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THE EVIDENCE SO FAR
Alan D. Ogilvie and Anthony J. Harmar
MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside
Park, Edinburgh, United Kingdom
The serotonin transporter is one of a family of
sodium-dependent monoamine transporters,
which includes those for norepinephrine, dopa-
mine, glycine, and GABA. Many antidepressant
agents function by inhibiting the serotonin trans-
porter, and the highly effective serotonin selec-
tive reuptake inhibitors (SSRIs), such as fluoxe-
tine (Prozac), do so very specifically. In 1996
molecular genetic studies demonstrated an asso-
ciation between allelic variation in the gene for
the serotonin transporter and susceptibility to
affective disorder (depression and manic depres-
sive illness), and they suggested that this gene
may be important in determining the inheritance
of certain "normal" personality traits, most no-
tably, those grouped under the heading 'neurot-
icism." In addition, the molecular biology of reg-
ulation of the serotonin transporter gene is




The serotonin transporter is a member of a very
ancient family of proteins present in organisms
ranging from bacteria to humans. Primitive
members of this protein family probably evolved
to enable cells to accumulate metabolically im-
portant small molecules or to respond to osmotic
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stress by intracellular accumulation of high con-
centrations of small organic solutes (osmolytes)
in exchange for inorganic ions (electrolytes). In
brain, similar proteins fulfill the more specialized
function of terminating the action of neurotrans-
mitters by removing them from the synaptic cleft
and recycling them into the neurotransmitter
pool.
The evidence for dysfunction of the seroton-
ergic system in affective disorder is compelling.
Levels of the serotonin metabolite 5-hydroxyin-
doleacetic acid (5-HIAA) are decreased in de-
pressed patients, especially those likely to com-
mit suicide (reviewed in ref. 1). There is also
evidence for reduced plasma levels of trypto-
phan, the amino acid precursor of serotonin, in
depression (2,3), and tryptophan depletion
causes a lowering of mood in normal subjects
and in recovered depressed patients (4). In addi-
tion, withdrawal of L-tryptophan treatment ap-
pears to precipitate relapse in chronically de-
pressed patients (5). Reports of abnormalities in
the binding sites for imipramine in blood plate-
lets and brain of patients (6,7) suggest altered
function and/or regulation of the serotonin
transporter in affective disorder. Imipramine was
one of the first drugs used to effectively treat
depressive illness (8,9). It is a tricyclic antidepres-
sant that nonselectively inhibits the uptake of
norepinephrine and serotonin. Serotonin selec-
tive reuptake inhibitors (SSRIs) such as fluvox-
amine, fluoxetine, and paroxetine target the se-
rotonin transporter specifically. These drugs
were developed in a successful strategy to retain
the efficacy of the tricyclic compounds, while
reducing side effects and toxicity (10).
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FIG. 1. Structure of the polymorphic regions of the serotonin transporter gene (14,15,21)
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GENETIC VARIATION IN THE
SEROTONIN TRANSPORTER
Following the cloning of the cDNA (11,12) en-
coding the human serotonin transporter, Lesch
and colleagues (13) examined its primary struc-
ture in patients with affective disorder. Sequenc-
ing of the protein coding region failed to reveal
changes in the deduced amino acid sequence,
and only one base substitution, representing a
silent polymorphism, was found in a single pa-
tient. Subsequent studies have focused on the
role of polymorphisms in noncoding regions of
the gene in the etiology of affective and related
psychiatric disorders and in determining normal
personality traits that may contribute to suscep-
tibility to these disorders.
Polymorphism in Intron 2
The first polymorphic region described was a
variable number tandem repeat (VNTR) in the
second intron of the gene (14) that contains 9,
10, or 12 copies of a 16-17 bp motif (15) (Fig. 1).
Although one report suggested that different al-
lelic forms may exist in a non-Caucasian (Japa-
nese) population (16), subsequent sequencing
has not confirmed this (Battersby, Kunugi, Ogil-
vie et al., unpublished results). Several studies
have now demonstrated an association between
allelic forms at this locus and susceptibility to
unipolar and to bipolar disorder. We have dem-
onstrated an association between the rare 9 re-
peat form of the VNTR and risk of both unipolar
(15) and bipolar disorder (17) in a Scottish pop-
ulation. This association was not found in Ger-
man (18) or Japanese (16) patients, but subse-
quent studies have found an increased frequency
of the 12 repeat allele in patients with bipolar
disorder (19,20) in independent samples. This is
also the case when the Japanese data is recon-
sidered in light of the correct sequence data (16).
It is not clear whether allelic variation at this
VNTR may directly influence expression of the
transporter in the central nervous system (CNS)
or whether this polymorphism is in linkage dis-
equilibrium with a nearby locus of importance.
Polymorphism in the 5' Flanking Region
The second polymorphism of interest lies 1.2 kb
upstream of the promoter of the gene where two
relatively common allelic forms (528 bp "long"
and 484 bp "short") of a GC-rich repetitive se-
quence have been described (21) (Fig. 1). In vitro
studies of the functional effects of this polymor-
phism in the context of the serotonin transporter
promoter showed that the long variant is associ-
ated with a 3-fold higher transcriptional activity
and increased responsiveness to stimulation by
forskolin or phorbol ester. The long variant is
also significantly more potent in repressing tran-
scriptional activity when fused to a heterologous
promoter. Serotonin transporter mRNA levels
and serotonin uptake capacity were reduced in
lymphoblastoid cell lines derived from individu-
als with one or two copies of the short allele
compared with those from long homozygotes
(22). A recent report (23) has shown that the
short variant of the polymorphic region was sig-
nificantly more frequent in patients with bipolar
and unipolar affective disorder, which suggests
that the polymorphism may have functional
91
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consequences. In addition, it has been reported
(24) that allelic variation at this locus correlates
with anxiety-related personality traits, which
may in turn be associated with increased risk of
affective disorder (25). It thus remains to be es-
tablished whether this locus directly predisposes
a person to affective disorder or does so indi-
rectly, mediating its effect by personality factors.
FUTURE DIRECTIONS
In summary, there is evidence to suggest that, in
a subgroup of patients, a locus within or close to
the serotonin transporter gene may predispose to
affective disorder, either directly or as a conse-
quence of its effect on personality. There are two
possible mechanisms that may explain the asso-
ciation between the two polymorphisms de-
scribed above and the risk of affective disorder. It
is possible that the level of serotonin transporter
gene transcription may be influenced by the se-
quences of the repetitive elements in either or
both of the polymorphic regions. Alternatively,
they may be in linkage disequilibrium with an-
other, more directly relevant gene locus. The fact
that different allelic forms of the intron-2 poly-
morphism appear to be associated with affective
disorder in different populations suggests linkage
dysequilibrium with a nearby locus of biological
significance. To assess the importance of the 5'
polymorphic region, studies of its influence on
the expression and regulation of the serotonin
transporter gene in human subjects are required.
Although it is clearly important to unravel the
biological consequences of these two polymor-
phisms, it is also plausible that the locus of im-
portance lies elsewhere in the region. More de-
tailed analysis of this region may ultimately yield
findings of great interest.
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